TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15716710

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg/day)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combined (losartan 50 mg/day plus ramipril 5 mg/day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (12.5 mg/day) added as needed
Number of subjects: 51
Study: 12742978

Group type: EXPERIMENTAL
Intervention: Rapamycin (n=22)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (continued current immunosuppression, n=24)
Number of subjects: 46
Study: 10496543

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sham Acupressure
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control
Number of subjects: 84
Study: 8721801

Group type: EXPERIMENTAL
Intervention: Enrollment in CAST
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Demographic variables (e.g., being male, not having medical insurance)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Episodes of ventricular tachycardia
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Health beliefs (e.g., extra beats are harmful, a higher degree of general health concern)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Clinical trial staff interaction and timing of recruitment
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Health care reform improving access to medical insurance coverage
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Modifiable variables
Number of subjects: 400
Study: 1918659

Group type: EXPERIMENTAL
Intervention: Lithium discontinuation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inositol administration
Number of subjects: 0
Study: 7071805

Group type: COMPARATOR
Intervention: Subcutaneous calcium heparin (5,000 units eight-hourly)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium heparin monitored by maintaining the standardised APTT at 50 secs
Number of subjects: 0
Study: 6367723

Group type: EXPERIMENTAL
Intervention: Betaxolol hydrochloride, 0.5%
Number of subjects: 46

Group type: COMPARATOR
Intervention: Timolol maleate, 0.5%
Number of subjects: 46
Study: 31215471

Group type: EXPERIMENTAL
Intervention: Surgical excision of the keloid scar followed by sub-dermal injection of triamcinolone acetonide (2 ampules of 10 mg/1 ml each) at the time of wound closure.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Surgical excision of the keloid scar without corticosteroid injection (control group).
Number of subjects: 150
Study: 29912070

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard of care plus three reading visits
Number of subjects: 60
Study: 26782027

Group type: EXPERIMENTAL
Intervention: Single puncture arthrocentesis
Number of subjects: 40

Group type: COMPARATOR
Intervention: Double puncture arthrocentesis
Number of subjects: 40
Study: 25285751

Group type: EXPERIMENTAL
Intervention: Tailored intervention (telephone calls and access to a mom-centric website)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Standard PA website (control)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Tailored intervention
Number of subjects: 311
Study: 22549600

Group type: EXPERIMENTAL
Intervention: Qigong massage methodology delivered by parents and trainers
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study: 19800817

Group type: EXPERIMENTAL
Intervention: Continuous ultrafiltration
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional ultrafiltration
Number of subjects: 60
Study: 18046028

Group type: EXPERIMENTAL
Intervention: Eltrombopag 30 mg daily
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Eltrombopag 50 mg daily
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Eltrombopag 75 mg daily
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 16237623

Group type: EXPERIMENTAL
Intervention: Active experimental group (endurance exercise, 40 minutes per session at 70-90% heart rate reserve, 7 days/week)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sedentary experimental group (endurance exercise, 40 minutes per session at 70-90% heart rate reserve, 7 days/week)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control groups (active and sedentary)
Number of subjects: 40
Study: 14516881

Group type: EXPERIMENTAL
Intervention: Biphasic truncated exponential (BTE) waveform
Number of subjects: 101

Group type: COMPARATOR
Intervention: Biphasic rectilinear (BRL) waveform
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both BTE and BRL waveforms
Number of subjects: 101
Study: 12024980

Group type: EXPERIMENTAL
Intervention: Pefloxacin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Augmentin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Chloramphenicol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cefpirom
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 10
Study: 8544782

Group type: COMPARATOR
Intervention: Conventional isotope dilution technique (Cold-GINF)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Constant specific activity method (Hot-GINF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-dose insulin infusion (5, 10, 20 mU . m-2 . min-1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: High-dose insulin infusion (40, 80, 160 mU . m-2 . min-1)
Number of subjects: 30
Study: 1987006

Group type: EXPERIMENTAL
Intervention: 96 meq sodium
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 6846125

Group type: EXPERIMENTAL
Intervention: Oral verapamil
Number of subjects: 20
Study: 31283555

Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 204

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 204

Group type: COMPARATOR
Intervention: Routine care (no acupuncture treatment)
Number of subjects: 204
Study: 29157273

Group type: EXPERIMENTAL
Intervention: Daikenchuto (TJ-100)
Number of subjects: 40
Study: 25623520

Group type: EXPERIMENTAL
Intervention: Mud-bath therapy (12 mudpacks and 12 thermal baths) with continued TNF inhibitor treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Pharmacological therapy alone (TNF inhibitors)
Number of subjects: 36
Study: 24964805

Group type: EXPERIMENTAL
Intervention: Quadrivalent meningococcal conjugate vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quadrivalent meningococcal polysaccharide vaccine
Number of subjects: 0
Study: 21615805

Group type: EXPERIMENTAL
Intervention: Classical ketogenic diet
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Medium chain triglyceride ketogenic diet
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 91
Study: 19755070

Group type: EXPERIMENTAL
Intervention: Preoperative footbath with chlorhexidine gluconate (Hibitane) 20 minutes before surgery
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo footbath
Number of subjects: 44
Study: 17312228

Group type: EXPERIMENTAL
Intervention: PCEA+AMB (n = 21, 0.1% ropivacaine + fentanyl 2 microg/mL, bolus 5 mL, lockout 10 min, basal automated boluses of 5 mL/h)
Number of subjects: 42

Group type: COMPARATOR
Intervention: PCEA+BCI (n = 21, 0.1% ropivacaine + fentanyl 2 microg/mL, bolus 5 mL, lockout 10 min, basal infusion 5 mL/h)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: PCEA+AMB
Number of subjects: 42

Group type: COMPARATOR
Intervention: PCEA+BCI
Number of subjects: 42
Study: 15211441

Group type: EXPERIMENTAL
Intervention: n-3 Polyunsaturated fatty acids (PUFAs) 2.4 g for 8 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control treatment (olive oil)
Number of subjects: 64
Study: 11208997

Group type: EXPERIMENTAL
Intervention: 0K dialysate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1K dialysate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2K dialysate
Number of subjects: 12
Study: 10696320

Group type: EXPERIMENTAL
Intervention: Tropicamide 1% spray
Number of subjects: 34

Group type: COMPARATOR
Intervention: Tropicamide 1% eye drops
Number of subjects: 34
Study: 9156934

Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (EACA) given in a daily dose of 85-230 mg/kg for 1-11 days
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (EACA) given with corticosteroids
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (EACA)
Number of subjects: 13
Study: 1860199

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 6211996

Group type: EXPERIMENTAL
Intervention: Clindamycin and gentamicin
Number of subjects: 130

Group type: COMPARATOR
Intervention: Cefamandole
Number of subjects: 130

Group type: COMPARATOR
Intervention: Cefoperazone
Number of subjects: 130
Study: 29618132

Group type: EXPERIMENTAL
Intervention: Isometric exercise (knee extension, 30% maximum voluntary contraction for three minutes)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Quiet rest
Number of subjects: 30
Study: 29271276

Group type: EXPERIMENTAL
Intervention: Telephone-delivered CBT with self-help, CBT recovery manual (TS)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: High support CBT (HS - TAU plus TS plus group sessions)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 89
Study: 27974112

Group type: EXPERIMENTAL
Intervention: Caffeine treatment
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (no caffeine treatment)
Number of subjects: 59
Study: 23887680

Group type: COMPARATOR
Intervention: No muscle relaxant (group NR)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Muscle relaxant (group R)
Number of subjects: 86
Study: 23673265

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided corticosteroid injection
Number of subjects: 166

Group type: COMPARATOR
Intervention: Open surgical release of A1-pulley
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 166
Study: 20835573

Group type: EXPERIMENTAL
Intervention: Bovine bone morphogenetic proteins associated with collagen membrane (test sites)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Collagen membrane only (control sites)
Number of subjects: 15
Study: 18156990

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a (40KD) + ribavirin (Peg‐IFN/RBV) for 48 weeks
Number of subjects: 857

Group type: COMPARATOR
Intervention: Conventional interferon alfa‐2a + ribavirin (IFN/RBV)
Number of subjects: 857

Group type: COMPARATOR
Intervention: Peginterferon alfa‐2a (40KD) + placebo (Peg‐IFN)
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Peg‐IFN/RBV
Number of subjects: 857
Study: 16175189

Group type: EXPERIMENTAL
Intervention: Irinotecan (110 mg/m² on day 1 and 100 mg/m² on day 8) plus cisplatin (80 mg/m² on day 8)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Cisplatin (80 mg/m² on day 1)
Number of subjects: 147
Study: 12970994

Group type: EXPERIMENTAL
Intervention: Group based psychosocial rehabilitation (two outpatient counselling sessions focusing on risk factor reduction and psychosocial adjustment)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Group based psychosocial rehabilitation
Number of subjects: 200
Study: 10376783

Group type: COMPARATOR
Intervention: Iron supplementation (Group A)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Zinc supplementation (Group B)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Iron plus Zinc supplementation (Group C)
Number of subjects: 38
Study: 8808720

Group type: EXPERIMENTAL
Intervention: T8 lymphocytes in patients with complete response, 1 month after operation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group T8 lymphocytes, 1 month after operation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: T8 lymphocytes in patients with partial response, 1 month after operation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: T8 lymphocytes in patients with no effect, 1 month after operation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: T8 lymphocytes in all patients, 3 months after operation
Number of subjects: 30
Study: 1417429

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride tricyclic pharmacotherapy
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Cognitive therapy and pharmacotherapy combined
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 107
Study: 4043659

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid, 1000 mg/day for 1 month
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo for 1 month
Number of subjects: 12
Study: 30938903

Group type: EXPERIMENTAL
Intervention: Limb immobilisation for 2 hours after sheath removal
Number of subjects: 150

Group type: COMPARATOR
Intervention: Limb immobilisation for 4 hours after sheath removal (Control)
Number of subjects: 150
Study: 30175876

Group type: EXPERIMENTAL
Intervention: Submandibular gland transfer (SMGT) and intensity-modulated radiotherapy (IMRT)
Number of subjects: 40
Study: 27530375

Group type: EXPERIMENTAL
Intervention: Ingenol mebutate gel (IMB) - 3 days treatment cycle
Number of subjects: 22

Group type: COMPARATOR
Intervention: Daylight photodynamic therapy (dlPDT) - single session
Number of subjects: 22
Study: 23983039

Group type: EXPERIMENTAL
Intervention: TCZ‐SC (subcutaneous tocilizumab) 162 mg every 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: TCZ‐IV (intravenous tocilizumab) 8 mg/kg every 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TCZ‐SC
Number of subjects: 0

Group type: COMPARATOR
Intervention: TCZ‐IV
Number of subjects: 0
Study: 23090233

Group type: EXPERIMENTAL
Intervention: Low-fidelity suture training model (synthetic ethylene-vinyl acetate bench model)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-fidelity suture training model (pig feet skin bench model)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Theoretical suture training alone (control)
Number of subjects: 36
Study: 21542401

Group type: EXPERIMENTAL
Intervention: Nitroglycerin application (Nitroderm)
Number of subjects: 6426

Group type: COMPARATOR
Intervention: Control group (no nitroglycerin application)
Number of subjects: 6426
Study: 18722223

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg twice daily
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 15687143

Group type: EXPERIMENTAL
Intervention: Restricted group
Number of subjects: 265

Group type: COMPARATOR
Intervention: Unrestricted group
Number of subjects: 265
Study: 12640021

Group type: EXPERIMENTAL
Intervention: High dose recombinant human IL-6 (HiIL-6; n = 6)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low dose IL-6 (LoIL-6; n = 6)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline (Control; n = 6)
Number of subjects: 18
Study: 10232639

Group type: EXPERIMENTAL
Intervention: Lactulose (25 g)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fructooligosaccharides (25 g)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sucrose (50 g)
Number of subjects: 40
Study: 8904629

Group type: EXPERIMENTAL
Intervention: Frusemide
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7901582

Group type: EXPERIMENTAL
Intervention: Anticoagulation
Number of subjects: 1007
Study: 3121350

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg orally after 90 min of insulin infusion)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo (given to control group)
Number of subjects: 5
Study: 28455106

Group type: EXPERIMENTAL
Intervention: Late dinner (eating late)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Early dinner (eating early)
Number of subjects: 0
Study: 26351904

Group type: EXPERIMENTAL
Intervention: 6-month physical activity program (exercising at sport centres at least once per week for 6 months)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 6-month physical activity program
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 104
Study: 25481340

Group type: EXPERIMENTAL
Intervention: Intraluminal technique using an Aintree intubating catheter
Number of subjects: 30

Group type: COMPARATOR
Intervention: Extraluminal technique using a nasal route alongside the LT
Number of subjects: 30
Study: 23490225

Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg once-daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Formoterol 12 μg twice-daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Indacaterol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Formoterol
Number of subjects: 20
Study: 21465776

Group type: EXPERIMENTAL
Intervention: Hyperbaric gaseous cryotherapy using carbon dioxide at -78 degrees C
Number of subjects: 0
Study: 19541503

Group type: EXPERIMENTAL
Intervention: Oral unsaturated fat supplements (90mL of Calogen and 4 capsules of Pikasol)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No supplements (control)
Number of subjects: 40
Study: 16885013

Group type: EXPERIMENTAL
Intervention: CHF3381 (500 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Gabapentin (1,200 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 15020359

Group type: EXPERIMENTAL
Intervention: T(2) weighted images
Number of subjects: 30

Group type: COMPARATOR
Intervention: T(1) weighted images
Number of subjects: 30
Study: 11831481

Group type: EXPERIMENTAL
Intervention: Nitrous oxide sedation (NO)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Applied relaxation (AR)
Number of subjects: 62

Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 62
Study: 10408951

Group type: EXPERIMENTAL
Intervention: Screening for prostate cancer
Number of subjects: 32000

Group type: COMPARATOR
Intervention: Other studies and mechanisms of screening
Number of subjects: 32000
Study: 8154645

Group type: EXPERIMENTAL
Intervention: Cholesterol reduction treatment
Number of subjects: 14

Group type: COMPARATOR
Intervention: Cholesterol levels lower than 4.14 mmol/L (160 mg/dL)
Number of subjects: 14
Study: 2680584

Group type: EXPERIMENTAL
Intervention: Theophylline (6 mg.kg‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PAF (inhaled in five successive doses every 15 min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PAF
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 8
Study: 769707

Group type: EXPERIMENTAL
Intervention: 600 mg D(-)penicillamine daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1200 mg D(-)penicillamine daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard regimen of therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 600 mg and 1200 mg D(-)penicillamine
Number of subjects: 0
Study: 31377568

Group type: EXPERIMENTAL
Intervention: CHW-based intervention (6 household visits over 12 months)
Number of subjects: 2312

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 2312
Study: 29122262

Group type: EXPERIMENTAL
Intervention: Geranium aroma (3 drops of geranium essential oil inhaled for 20 minutes a day for 2 days)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (3 drops of placebo inhaled for 20 minutes a day for 2 days)
Number of subjects: 80
Study: 24583294

Group type: EXPERIMENTAL
Intervention: Deferred stenting
Number of subjects: 101

Group type: COMPARATOR
Intervention: Immediate stenting
Number of subjects: 101
Study: 23684411

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg once every 12 weeks
Number of subjects: 425

Group type: COMPARATOR
Intervention: Zoledronic acid 4 mg once every 4 weeks
Number of subjects: 425
Study: 20368475

Group type: EXPERIMENTAL
Intervention: Joyful music
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Anxiety-provoking music
Number of subjects: 10
Study: 18770080

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 163
Study: 15668361

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg once daily
Number of subjects: 404

Group type: COMPARATOR
Intervention: Celecoxib 200 mg once daily
Number of subjects: 404

Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Rofecoxib vs Celecoxib
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Rofecoxib vs Naproxen
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 404

Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 404

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 404
Study: 12544691

Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole twice daily with 1000 mg amoxicillin twice daily and 400 mg clarithromycin twice daily for 1 week
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: 10 mg rabeprazole twice daily with 1000 mg amoxicillin twice daily and 400 mg clarithromycin twice daily for 1 week
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: 20 mg rabeprazole twice daily with 1000 mg amoxicillin twice daily and 400 mg clarithromycin twice daily for 1 week
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Clarithromycin-sensitive strains
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Clarithromycin-resistant strains
Number of subjects: 145
Study: 10381247

Group type: EXPERIMENTAL
Intervention: Feldenkrais sessions
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham sessions
Number of subjects: 20
Study: 2112079

Group type: EXPERIMENTAL
Intervention: LNG-IUD
Number of subjects: 200

Group type: COMPARATOR
Intervention: Norplant-2
Number of subjects: 200
Study: 227680

Group type: EXPERIMENTAL
Intervention: Negative ionization
Number of subjects: 9

Group type: COMPARATOR
Intervention: Positive ionization
Number of subjects: 9
Study: 31296368

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 28370434

Group type: EXPERIMENTAL
Intervention: Reflectance confocal microscopy (RCM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Punch biopsy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: RCM
Number of subjects: 100